Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)

This study has been terminated.
Sponsor:
Information provided by:
MedtronicNeuro
ClinicalTrials.gov Identifier:
NCT00157755
First received: September 8, 2005
Last updated: February 23, 2010
Last verified: December 2009

September 8, 2005
February 23, 2010
June 2002
December 2008   (final data collection date for primary outcome measure)
Percent Reduction in Frequency of Weekly Vomiting Episodes When the Device is Turned ON, Relative to When the Device is Turned OFF [ Time Frame: 4.5 months and 7.5 months ] [ Designated as safety issue: No ]
Diaries were used to record daily vomiting episodes for 28 days prior to each office follow-up visit. The weekly vomiting frequency (WVF) was based on the average number of weekly vomiting episodes recorded in the patient diary. The percent reduction is calculated as ((WVF during OFF - WVF during ON)/ (WVF during OFF))*100%. A positive reduction represents an improvement in WVF when the device was ON.
Reduction in frequency of weekly vomiting episodes
Complete list of historical versions of study NCT00157755 on ClinicalTrials.gov Archive Site
  • Percent Reduction in Symptom Score When the Device is Turned ON, Relative to When the Device is Turned OFF [ Time Frame: 4.5 months and 7.5 months ] [ Designated as safety issue: No ]
    A symptom interview was conducted at each visit to assess vomiting, nausea, early satiety, bloating, postprandial fullness, epigastric pain and epigastric burning. The scale for each symptom ranges from 0 to 4, with 0 being absence of symptoms and 4 being extremely frequent (≥ 7 episodes per week). Total symptom score (TSS) is the sum of the individual frequency symptom scores. The percent reduction is calculated as ((TSS during OFF - TSS during ON)/ (TSS during OFF))*100%. A positive reduction represents an improvement in TSS when the device was ON.
  • Percent Reduction in the Frequency of Weekly Vomiting Episodes at 12 Months Compared to Baseline [ Time Frame: baseline and 12 months ] [ Designated as safety issue: No ]
    Diaries were used to record daily vomiting episodes for 28 days prior to each office follow-up visit. The weekly vomiting frequency (WVF) was based on the average number of weekly vomiting episodes recorded in the patient diary. The percent reduction is calculated as ((WVF at baseline - WVF at 12 months)/ (WVF at baseline))*100%. A positive reduction represents an improvement in WVF at 12 months.
  • 1. Reduction in symptoms of gastroparesis
  • 2. Long-term reduction in the frequency of weekly vomiting episodes
Not Provided
Not Provided
 
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
Gastric Stimulation for Vomiting, Nausea and Related Symptoms Associated With Gastroparesis Using Enterra® Gastric Stimulation System

This study is to evaluate the safety and effectiveness of gastric stimulation in the reduction of nausea and vomiting in patients with gastroparesis using an approved Humanitarian device. There are two cohorts in this study based on etiology, one for diabetic and one for idiopathic.

A maximum of 150 patients (75 diabetic and 75 idiopathic) from up to 15 centers in the United States will be followed closely for twelve months and then once a year after that until the study closes.

If you are someone suffering with symptoms of gastroparesis despite trying oral medications, you may be eligible to participate in a clinical study using a surgically implanted gastric stimulator.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Gastroparesis
Device: Enterra Therapy
Gastric electrical stimulation using Enterra Therapy.
Not Provided
McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010 Nov;8(11):947-54; quiz e116. doi: 10.1016/j.cgh.2010.05.020. Epub 2010 Jun 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
87
March 2009
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or Female at least 18 years of age
  • Diagnosed with gastroparesis due to diabetes or an unknown cause (idiopathic)
  • Have tried prokinetic (help the stomach empty quicker) and antiemetic (help decrease symptoms of nausea and vomiting) medications for a minimum of one month, unless you're unable to take these types of medications
  • Have symptoms of gastroparesis that have required treatment for at least one year
  • Experience at least 7 episodes of vomiting during a seven consecutive day period on a 28-day diary
  • Willing and able to completely and accurately fill out a diary and questionnaires throughout the study
  • Have gastric retention of greater than 10% at four hours, or greater than 60% at two hours (if unable to complete the four-hour test) on a Gastric Emptying Test (GET)

Exclusion Criteria:

  • Gastroparesis caused by a specific diagnosed illness other than diabetes
  • Current eating disorder or diagnosed swallowing disorder
  • Previous stomach surgeries
  • Taking narcotic pain-relievers daily for abdominal pain
  • Diagnosed with drug or alcohol dependency within 1 year before the study
  • Life expectancy less than one year
  • Have other implantable devices such as pacemakers
  • Pregnancy or planned pregnancy
  • Plan to receive diathermy treatment
  • Have had radiation therapy of the upper abdomen
  • Plan on having an MRI performed
  • Currently participating in another investigational device or drug study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00157755
NDHF0025-70006
Not Provided
Darin Lerew, Sr. Clinical Manager, Medtronic Neuromodulation
MedtronicNeuro
Not Provided
Study Director: Darin R Lerew, PhD Medtronic
MedtronicNeuro
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP